WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017189613) METHODS OF USING FASN INHIBITORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/189613 International Application No.: PCT/US2017/029469
Publication Date: 02.11.2017 International Filing Date: 25.04.2017
IPC:
C07D 401/04 (2006.01) ,C07D 403/04 (2006.01) ,C07D 471/04 (2006.01)
Applicants: FORMA THERAPEUTICS, INC.[US/US]; 500 Arsenal Street Suite 100 Watertown, Massachusetts 02472, US
Inventors: MILLAN, David S.; US
LU, Wei; US
Agent: REARICK, John P.; US
AUGST, Alexander D.; US
BUTEAU, Kristen C.; US
CAHILL, John J.; US
HAULBROOK, William R.; US
HOFFMAN-LUCA, Cassandra Gianna; US
JARRELL, Brenda Herschbach; US
KLEIN, Daniel A.; US
LI, Xiaodong; US
LYON, Charles E.; US
MEDINA, Rolando; US
MONROE, Margo R.; US
NGUYEN, Suzanne P.; US
NIHAN, Danielle M.; US
PACE, Nicholas J.; US
PYSHER, Paul A.; US
REESE, Brian E.; US
ROHLFS, Elizabeth M.; US
SAHR, Robert N.; US
SCHONEWALD, Stephanie L.; US
SHAIKH, Nishat A.; US
SHINALL, Michael A.; US
SHORE, David E.; US
SMITH, Maria C.; US
SUH, Su Kyung; US
VETTER, Michael L.; US
VRABLIK, Tracy L.; US
WANG, Gang; US
Priority Data:
62/327,16725.04.2016US
Title (EN) METHODS OF USING FASN INHIBITORS
(FR) PROCÉDÉS D'UTILISATION D'INHIBITEURS DE FASN
Abstract:
(EN) The present disclosure relates to methods of treating, preventing or ameliorating a TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a FASN inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
(FR) La présente invention concerne des méthodes de traitement, de prévention ou de soulagement d'une maladie ou d'un trouble à médiation par TH17 ou CSF1 tel que le cancer, les troubles immunologiques, et l'obésité par administration à un patient en ayant besoin d'une quantité thérapeutiquement efficace d'un inhibiteur de FASN, ou d'un sel, hydrate, solvate, promédicament, stéréoisomère ou tautomère pharmaceutiquement acceptable de celui-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)